Quick Answer
Context Therapeutics Inc. reported Total Assets of $68.49 million for the year ending 2025.
- Context Therapeutics Inc. showed a decrease of -30.2% in Total Assets from 2024 to 2025.
- This data is from Context Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $2.26 million | Q1 2022: $47.03 million | Q2 2022: $44.70 million | Q3 2022: $42.08 million | Q1 2023: $31.97 million | Q2 2023: $27.76 million | Q3 2023: $22.99 million | Q1 2024: $11.05 million | Q2 2024: $102.71 million | Q3 2024: $86.33 million | Q1 2025: $92.97 million | Q2 2025: $87.15 million | Q3 2025: $79.23 million.
- Over the full 6 years of available data (2020 to 2025), Context Therapeutics Inc.'s Total Assets has grown by 14,556.1%.
- Historical annual values: Fiscal year 2025: $68.49 million | Fiscal year 2024: $98.13 million | Fiscal year 2023: $16.06 million | Fiscal year 2022: $37.97 million | Fiscal year 2021: $51.31 million | Fiscal year 2020: $467.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: